Pediatric Infection and Vaccine

The Korean Society of Pediatric Infectious Diseases (대한소아감염학회)
권호 표지

Reappraisal of Live Vaccines and Immunity in These Modern Days

현대에서의 생백신과 이에 대한 면역반응의 재평가

  • Kim, Kyung Hyo (Department of Pediatrics, School of Medicine, Ewha Womans University)
  • 김경효 (이화여자대학교 의과대학 소아과학교실)
  • Received : 2009.05.07
  • Accepted : 2009.06.05
  • Published : 2009.06.25
Download PDF
⟨ Previous Next ⟩

Abstract

The vaccines has been developed over the first two hundred years since Jenner's smallpox vaccination. In modern days, vaccination has had the largest impact on the incidence and persistence of infections. Although natural infection induces lifelong immunity, the assumption that the vaccine also confers permanent protection has been reconsidered following outbreaks of measles in students who had been vaccinated 15-20 years prior to infection in the US in the 1980s. Clinical studies have proposed several mechanisms such as vaccine failure in some individuals and the subsequent loss of immunity after vaccination. An ideal vaccine is relatively easy to define, but few real vaccines approach the ideal. Many difficulties account for the failure in producing these ideal vaccines. However, recent advances in methods for studying immune response to pathogens have provided a better understanding of immune mechanisms. Based on these findings, the development of good vaccine formulations allowing stimulation of optimal and prolonged protective immunity and immunization policies or schedules should lead to the introduction of vaccines for previously resistant organisms.

Keywords

References

  1. Plotkin SL, Plotkin SA. A short history of vaccination. In: Plotkin SA, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia: WB Saunders Co, 2004:1-16.
  2. Chen RT, Markowitz LE, Albrecht P. Measles antibodies: re-evaluation of protective titers. J Infect Dis 1990;162:1036-62. https://doi.org/10.1093/infdis/162.5.1036
  3. Gustafson TL, Lievens AW, Brunell PA, Moellenberg RG, Buttery CM, Sehulster LM. Measles outbreak in a fully immunized secondary-school population. N Engl J Med. 1987;316:771-4.  https://doi.org/10.1056/NEJM198703263161303
  4. Whittle HC, Aaby P, Samb B, Jensen H, Bennet J, Simondon F. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa. Lancet 1999;353:98-102. https://doi.org/10.1016/S0140-6736(98)02364-2
  5. Mossong J, Muller CP. Modelling measles re-emergence as a result of waning of immunity in vaccinated population. Vaccine 2003:21:4597-603. https://doi.org/10.1016/S0264-410X(03)00449-3
  6. Mossong J, Nokes J, Edmunds DJ, Cox WJ, Ratman MJ, Muller CP. Modelling the impact of subclinical measles transmission in vaccinated populations with waning immunity. Am J Epidemiol 1999;150:1238-49. https://doi.org/10.1093/oxfordjournals.aje.a009951
  7. Rouderfer V, Becker NG, Hethcote HW. Waning immunity and its effect on vaccination schedules. Math Biosci 1994;124:59-82. https://doi.org/10.1016/0025-5564(94)90024-8
  8. Galazka AM, Robertson SE, Oblapenko GP. Resurgence of diphtheria. Eur J Epidemiol 1995;11:95-105. https://doi.org/10.1007/BF01719954
  9. Teitelbaum MA, Edmunds M. Immunization and vaccine-preventable illness, United States, 1992-1997. Stat Bull Metrop Insur Co 1999;80:13-20.
  10. Wright SW. Pertussis infection in adults. South Med J 1998;91:702-8.
  11. Whittle HC, Aaby P, Samb B, Jensen H, Bennet J, Simondon F. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa. Lancet 1999;353:98-102. https://doi.org/10.1016/S0140-6736(98)02364-2
  12. Pelletier L, Chung P, Duclos P, Manga P, Scott J. A benefit-cost analysis of two dose measles immunization in Canada. Vaccine 1998;16:989-96. https://doi.org/10.1016/S0264-410X(97)00281-8
  13. Janaszek W, Gay NJ, Gut W. Measles vaccine efficacy during an epidemic in 1998 in the highly vaccinated population in Poland. Vaccine 2003;21:473-8. https://doi.org/10.1016/S0264-410X(02)00482-6
  14. Wenger JD, Ward JI: Haemophilus influenzae vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia: WB Saunders Co, 2004:229-68.
  15. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007;357:1903-15. https://doi.org/10.1056/NEJMoa066092
  16. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001;20: 63-75. https://doi.org/10.1097/00006454-200101000-00013
  17. Plotkin S. Correlates of vaccine-induced immunity. Clin Infect Dis 2008;47:401. https://doi.org/10.1086/589862
  18. Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonski GA, Bernier RH. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 1991;163:1-6. https://doi.org/10.1093/infdis/163.1.1
  19. Plotkin SA, Starr SE, Friedman HM, Gonczol E, Weibel RE. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis 1989;159:860-5. https://doi.org/10.1093/infdis/159.5.860
  20. Taranger J, Trollfors B, Lagergard T, Sundh V, Bryla DA, Schneerson R, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 2000;181:1010-3. https://doi.org/10.1086/315318
  21. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990;162: 1036-42. https://doi.org/10.1093/infdis/162.5.1036
  22. Permar SR, Klumpp SA, Mansfield KG, Kim WK, Gorgone DA, Lifton MA, et al. Role of CD8+ lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol 2003;77:4396-400. https://doi.org/10.1128/JVI.77.7.4396-4400.2003
  23. Permar SR, Klumpp SA, Mansfield KG, Carville AA, Gorgone DA, Lifton MA, et al. Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys. J Infect Dis 2004;190: 998-1005. https://doi.org/10.1086/422846
  24. Pan CH, Valsamakis A, Colella T, Nair N, Adams RJ, Polack FP, et al. Inaugural article: modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H encoding alphavirus replicon particles. Proc Natl Acad Sci USA 2005; 102:11581-8. https://doi.org/10.1073/pnas.0504592102
  25. Polack FP, Lee SH, Permar S, Manyara E, Nousari HG, Jeng Y, et al. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat Med 2000;6:776-81. https://doi.org/10.1038/77506
  26. Plotkin SA. Vaccination against the major infectious diseases. C R Acad Sci III 1999;322:943-51. https://doi.org/10.1016/S0764-4469(00)87191-7
  27. Kobiler D, Weiss S, Levy H, Fisher M, Mechaly A, Pass A, et al. Protective antigen as a correlative marker for anthrax in animal models. Infect Immun 2006;74: 5871-6. https://doi.org/10.1128/IAI.00792-06
  28. Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 2001; 19:4768-73. https://doi.org/10.1016/S0264-410X(01)00234-1
  29. Reuveny S, White MD, Adar YY, Kafri Y, Altboum Z, Gozes Y, et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 2001;69:2888-93. https://doi.org/10.1128/IAI.69.5.2888-2893.2001
  30. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg(Lond) 1972;70:767-77.
  31. Lee H, Nahm MH, Burton R, Kim KH. Immune response ininfants of the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol 2009;16:376-81. https://doi.org/10.1128/CVI.00344-08
  32. Horstmann DM. Viral vaccines and their ways. Rev Infect Dis 1979;1:502-16. https://doi.org/10.1093/clinids/1.3.502
  33. Plotkin SA, Farquhar JD, Ogra PL. Immunologic properties of RA27-3 rubella virus vaccine: a comparison with strains presently licensed in the United States. JAMA 1973;225:585-90. https://doi.org/10.1001/jama.225.6.585